ASCO GUIDELINES Bundle

Immune-related Adverse Events from Immune Checkpoint Inhibitor Therapy

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475468

Contents of this Issue

Navigation

Page 44 of 71

45 Table 6. Renal Toxicities 6.2 Nephritis/Acute Kidney Injury — Follow Up Grading Management G1: Creatinine level increase of >0.3 mg/dL; creatinine 1.5–2.0× above baseline If improved to baseline: • Resume routine creatinine monitoring. G2: Creatinine 2–3× above baseline If improved to Grade 1: • Taper corticosteroids over at least 4 weeks before resuming treatment with routine creatinine monitoring. • If elevations persist >7 days or worsen and no other cause found, treat as Grade 3. G3: Creatinine >3× baseline or >4.0 mg/dL; hospitalization indicated If improved to Grade 1: • Taper corticosteroids over at least 4 weeks. • If elevations persist >3–5 days or worsen, consider additional immunosuppression (e.g., infliximab, azathioprine, cyclophosphamide (monthly), cyclosporine, mycophenolate). G4: Life-threatening consequences; dialysis indicated; creatinine 6× above baseline If improved to Grade 1: • Taper corticosteroids over at least 4 weeks. • If elevations persist >2–3 days or worsen, consider additional immunosuppression (e.g., infliximab, azathioprine, cyclophosphamide (monthly), cyclosporine, mycophenolate). (cont'd)

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Immune-related Adverse Events from Immune Checkpoint Inhibitor Therapy